Saturday, July 11, 2026

Drug profile · INN

denosumab-dssb

denosumab-dssb (DENOSUMAB-DSSB) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — denosumab-dssb
US status
approved
Class
Route
SUBCUTANEOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

denosumab-dssb (DENOSUMAB-DSSB) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN denosumab-dssb
Brand DENOSUMAB-DSSB
Route SUBCUTANEOUS
Formulation INJECTABLE

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is denosumab-dssb?

denosumab-dssb (DENOSUMAB-DSSB) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for denosumab-dssb?

DENOSUMAB-DSSB is a marketed brand name for denosumab-dssb. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of denosumab-dssb?

denosumab-dssb has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.